Business Description
MapLight Therapeutics Inc
NAICS : 541720
SIC : 2834
ISIN : US56565P1030
Total Employee Number:
133Description
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 55.47 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -154.9 | |||||
3-Year EPS without NRI Growth Rate | -152.9 | |||||
3-Year FCF Growth Rate | -148.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 34.81 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 88.47 | |||||
9-Day RSI | 77.14 | |||||
14-Day RSI | 70.04 | |||||
3-1 Month Momentum % | 29.15 | |||||
6-1 Month Momentum % | 63.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 22.91 | |||||
Quick Ratio | 22.91 | |||||
Cash Ratio | 21.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2 | |||||
Shareholder Yield % | 0.04 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -79.89 | |||||
ROA % | -73.82 | |||||
ROIC % | -332.11 | |||||
3-Year ROIIC % | -91.76 | |||||
ROC (Joel Greenblatt) % | -2507.71 | |||||
ROCE % | -82.42 | |||||
Moat Score | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.2 | |||||
Price-to-Tangible-Book | 4.2 | |||||
EV-to-EBIT | -6.56 | |||||
EV-to-Forward-EBIT | -7 | |||||
EV-to-EBITDA | -6.58 | |||||
EV-to-Forward-EBITDA | -4.96 | |||||
EV-to-FCF | -8.41 | |||||
| Price-to-Net-Current-Asset-Value | 5.44 | |||||
| Price-to-Net-Cash | 5.76 | |||||
Earnings Yield (Greenblatt) % | -15.24 | |||||
FCF Yield % | -9.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MPLT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MapLight Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.242 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 70.04 | ||
| 14-Day ATR ($) | 2.508661 | ||
| 20-Day SMA ($) | 30.672 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 12.24 - 37.61 | ||
| Shares Outstanding (Mil) | 45.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MapLight Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MapLight Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-12-04 | In 154 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 59 days | ||
| General meeting for 2026 | 2026-06-23 09:00 | 29.79 (+6.47%) | ||
| First quarter earnings results for 2026 | 2026-05-29 | 29.78 (+1.78%) | ||
| Annual report for 2025 | 2026-03-26 | 18.14 (+5.47%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 18.14 (+5.47%) | ||
| Third quarter earnings results for 2025 | 2025-12-04 | 16.92 (+19.91%) |
Show
Entries
MapLight Therapeutics Inc Frequently Asked Questions
What is MapLight Therapeutics Inc(MPLT)'s stock price today?
The current price of MPLT is $37.11. The 52 week high of MPLT is $37.61 and 52 week low is $12.24.
When is next earnings date of MapLight Therapeutics Inc(MPLT)?
The next earnings date of MapLight Therapeutics Inc(MPLT) is 2026-08-31 Est..
Does MapLight Therapeutics Inc(MPLT) pay dividends? If so, how much?
MapLight Therapeutics Inc(MPLT) does not pay dividend.
Guru Commentaries on NAS:MPLT
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on MapLight Therapeutics Inc
No articles.
Headlines
See More- 1
Jun 25, 2026
Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts
Seeking Alpha • 9:54am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers